TaniguchiN., “On the Basic Concept of “Nano-Technology',” in Proceedings of the International Conference of Production Engineering, Tokyo, Part II, Japan Society of Precision Engineering, 1974.
AsimovI., Fantastic Voyage: A Novel (Boston, Houghton Mifflin, 1966).
6.
BaumR., “Nanotechnology: Drexler and Smalley Make the Case for and against ‘Molecular Assemblers,’”Chemical & Engineering News (American Chemical Society), 81, no. 48 (2003): 37–42, available at <http://pubs.acs.org/cen/coverstory/8148/8148counterpoint.html> (last visited October 26, 2012).
FerrariM., “Cancer Nanotechnology: Opportunities & Challenges,”Nature Reviews in Cancer5, no. 3 (2005): 161–171; FerrariM., “Frontiers in Cancer Nanomedicine: Directing Mass Transport through Biological Barriers,”Trends in Biotechnology28, no. 4 (2010): 181–188. Salvador-MoralesC.ValenciaP. M.ThakkarA. B.SwansonE. W. and LangerR., “Recent Developments in Multifunctional Hybrid Nanoparticles: Opportunities and Challenges in Cancer Therapy,”Frontiers in Bioscience (Elite Ed.)4, no. 4 (2012): 529–545; LangerR., “Drug Delivery and Targeting,”Nature392, no. 6679, Supp. (1998): 5–10.
10.
FangJ.NakamuraH., and MaedaH., “The EPR Effect: Unique Features of Tumor Blood Vessels for Drug Delivery, Factors Involved, and Limitations and Augmentation of the Effect,”Advanced Drug Delivery Reviews63, no. 3 (2011): 136–151; MaedaH.WuJ.SawaT.MatsumuraY., and HoriK., “Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review,”Journal of Controlled Release65, No. 1-2 (2000): 271–284.
11.
BarenholzY. C., “Doxil® – The First FDA-Approved Nano-Drug: Lessons Learned,”Journal of Controlled Release, March, 29, 2012, available at <http://www.ncbi.nlm.nih.gov/pubmed/22484195> (last visited October 26, 2012); McGeeP., “Delivering on Nano's Promise,”Drug Discovery & Development Magazine9, no. 10 (2006): 12–18.
DavisM. E.ZuckermanJ. E.ChoiC. H.SeligsonD.TolcherA.AlabiC. A.YenY.HeidelJ. D., and RibasA., “Evidence of RNAi in Humans from Systemically Administered siRNA via Targeted Nanoparticles,”Nature464, no. 7291 (2010): 1067–1070; Calando Pharmaceuticals, “Safety Study of CALAA-01 to Treat Solid Tumor Cancers,” in ClinicalTrials.gov, Bethesda (MD): National Library of Medicine (U.S.), NLM Identifier: NCT00689065, available at <http://www.clinicaltrials.gov/ct2/show/NCT00689065> (last visited October 26, 2012); BIND Biosciences, “A Study of BIND-014 Given to Patients with Advanced or Metastatic Cancer,” in ClinicalTrials.gov, Bethesda (MD): National Library of Medicine (US), NLM Identifier: NCT01300533, available at <http://www.clinicaltrials.gov/ct2/show/NCT01300533> (last visited October 26, 2012).
14.
VishnuP. and RoyV., “Nab-Paclitaxel: A Novel Formulation of Taxane for Treatment of Breast Cancer,”Womens Health (London)6, no. 4 (2010): 495–506.
15.
Maier-HauffK.UlrichF.NestlerD.NiehoffH.WustP.ThiesenB.OrawaH.BudachV., and JordanA., “Efficacy and Safety of Intratumoral Thermotherapy Using Magnetic Iron-Oxide Nanoparticles Combined with External Beam Radiotherapy on Patients with Recurrent Glioblastoma Multiforme,”Journal of Neurooncology103, no. 2 (2011): 317–324.
16.
HuM.ChenJ.LiZ. Y.AuL.HartlandG. V.LiX.MarquezM., and XiaY., “Gold Nanostructures: Engineering Their Plasmonic Properties for Biomedical Applications,”Chemical Society Reviews35, no. 11 (2006): 1084–1094; HirschL. R.StaffordR. J.BanksonJ. A.SershenS. R.RiveraB.PriceR. E.HazleJ. D.HalasN. J., and WestJ. L., “Nanoshell-Mediated Near-Infrared Thermal Therapy of Tumors under Magnetic Resonance Guidance,”Proceedings of the National Academy of Sciences of the United States of America100, no. 23 (2003): 13549–13554.
17.
See Ferrari (2010), supra note 9.
18.
TasciottiE.LiuX.BhavaneR.PlantK.LeonardA. D.PriceB. K.ChengM. M.DecuzziP.TourJ. M.RobertsonF., and FerrariM., “Mesoporous Silicon Particles as a Multistage Delivery System for Imaging and Therapeutic Applications,”Nature Nanotechnology3, no. 3 (2008): 151–157.
19.
TanakaT.MangalaL. S.Vivas-MejiaP. E.Nieves-AliceaR.MannA. P.MoraE.HanH. D.ShahzadM. M.LiuX.BhavaneR.GuJ.FakhouryJ. R.ChiappiniC.LuC.MatsuoK.GodinB.StoneR. L.NickA. M.Lopez-BeresteinG.SoodA. K., and FerrariM., “Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles,”Cancer Research70, no. 9 (2010): 3687–3696.
20.
ShenH.YouJ.ZhangG.ZiemysA.LiQ.BaiL.DengX.ErmD. R.LiuX.LiC., and FerrariM., “Cooperative, Nanoparticle-Enabled Thermal Therapy of Breast Cancer,”Advanced Healthcare Materials1, no. 1 (2012): 84–89.
21.
AnantaJ. S.GodinB.SethiR.MoriggiL.LiuX.SerdaS. E.KrishnamurthyR.MuthupillaiR.BolskarR. D.HelmL.FerrariM.WilsonL. J., and DecuzziP., “Geometrical Confinement of Gadolinium-Based Contrast Agents in Nanoporous Particles Enhances T1 Contrast,”Nature Nanotechnology5, no. 11 (2010): 815–821.
22.
See Davis, supra note 13.
23.
PrakashS.KhanA., and PaulA., “Nanoscaffold Based Stem Cell Regeneration Therapy: Recent Advancement and Future Potential,”Expert Opinion on Biological Therapy10, no. 12 (2010): 1649–1661; Dolatshahi-PirouzA.NikkhahM.KolindK.DokmeciM. R., and KhademhosseiniA., “Micro- and Nanoengineering Approaches to Control Stem Cell-Biomaterial Interactions,”Journal of Functional Biomaterials2, no. 3 (2011): 88–106; MataA.PalmerL.Tejeda-MontesE., and StuppS. I., “Design of Biomolecules for Nanoengineered Biomaterials for Regenerative Medicine,”Methods in Molecular Biology811(2012): 39–49.
24.
DesaiT. A.HansfordD. J.KulinskyL.NashatA. H.RasG.TuJ.WangY.ZhangM., and FerrariM., “Nanopore Technology for Biomedical Applications,”Biomedical Microdevices2, no. 1 (1999): 11–40; FineD.GrattoniA.ZabreE.HusseinF.FerrariM., and LiuX., “A Low-Voltage Electrokinetic Nanochannel Drug Delivery System,”Lab on a Chip11, no. 15 (2011): 2526–2534; FineD.GrattoniA.HosaliS.ZiemysA.De RosaE.GillJ.MedemaR.HudsonL.KojicM.MilosevicM.BrousseauL.IIIGoodallR.FerrariM., and LiuX., “A Robust Nanofluidic Membrane with Tunable Zero-Order Release for Implantable Dose Specific Drug Delivery,”Lab on a Chip10, no. 22 (2010): 3074–3083; GrattoniA.ShenH.FineD.ZiemysA.GillJ. S.HudsonL.HosaliS.GoodallR.LiuX., and FerrariM., “Nanochannel Technology for Constant Delivery of Chemotherapeutics: Beyond Metronomic Administration,”Pharmaceutical Research28, no. 2 (2011): 292–300.
25.
DesaiT. A.ChuW. H.RasiG.Sinibaldi-VallebonaP.GuarinoE., and FerrariM., “Microfabricated Biocapsules Provide Short-Term Immunoisolation of Insulinoma Xenografts,”Biomedical Microdevices1, no. 2 (1999): 131–138; DesaiT. A.ChuW. H.TuJ.K.BeattieG. M.HayekA., and FerrariM., “Microfabricated Immunoisolating Biocapsules,”Iotechnology and Bioengineering57, no. 1 (1988): 118–120.
26.
BouamraniA.HuY.TasciottiE.LiL.ChiappiniC.LiuX., and FerrariM., “Mesoporous Silica Chips for Selective Enrichment and Stabilization of Low Molecular Weight Proteome,”Proteomics10, no. 3 (2010): 496–505; HillH. D. and MirkinC. A., “The Bio-Barcode Assay for the Detection of Protein and Nucleic Acid Targets Using DTT-Induced Ligand Exchange,”Nature Protocols1, no. 1 (2006): 324–336; GeorganopoulouD. G.ChangL.NamJ. M.ThaxtonC. S.MufsonE. J.KleinW. L., and MirkinC. A., “Nanoparticle-Based Detection in Cerebral Spinal Fluid of a Soluble Pathogenic Biomarker for Alzheimer's Disease,”Proceedings of the National Academy of Sciences of the United States of America102, no. 7 (2005): 2273–2276; FanR.VermeshO.SrivastavaA.YenB. K.QinL.AhmadH.KwongG. A.LiuC. C.GouldJ.HoodL., and HeathJ. R., “Integrated Barcode Chips for Rapid, Multiplexed Analysis of Proteins in Microliter Quantities of Blood,”Nature Biotechnology26, no. 12 (2008): 1373–1378; QinL.VermeshO.ShiQ., and HeathJ. R., “Self-Powered Microfluidic Chips for Multiplexed Protein Assays from Whole Blood,”Lab on a Chip9, no. 14 (2009): 2016–2020; BurgT. P.GodinM.KnudsenS. M.ShenW.CarlsonG.FosterJ. S.BabcockK., and ManalisS. R., “Weighing of Biomolecules, Single Cells and Single Nanoparticles in Fluid,”Nature446, no. 7139 (2007): 1066–1069; HuY.BouamraniA.TasciottiE.LiL.LiuX., and FerrariM., “Tailoring of the Nanotexture of Mesoporous Silica Films and Their Functionalized Derivatives for Selectively Harvesting Low Molecular Weight Protein,”ACS Nano4, no. 1 (2010): 439–451.
27.
BrennerM. K., “Personalized Medicine: Words That Mean Just What You Choose?”Molecular Therapy20, no. 2 (2012): 241–242; SakamotoJ. H.van de VenA. L.GodinB.BlancoE.SerdaS. E.GrattoniA.ZiemysA.BouamraniA.HuT.RanganathanS. I.De RosaE.MartinezJ. O.SmidC. A.BuchananR. M.LeeS. Y.SrinivasanS.LandryM.MeynA.TasciottiE.LiuX.DecuzziP., and FerrariM., “Enabling Individualized Therapy through Nanotechnology,”Pharmacology Research62, no. 2 (2010): 57–89.
28.
Id. (Sakamoto).
29.
See Desai, Fine (2010 & 2011), and Grattoni, supra note 24.
30.
See Prakash, Dolatshahi-Pirouz, and Mata, supra note 23.
31.
See Bouamrani, supra note 26; Sakamoto, supra note 27.
32.
ClintonW. J., “President Clinton's Address to Caltech on Science and Technology,” remarks by the President at Science and technology Event, California Institute of Technology, Pasadena, CA, 2002.
MalakoffD., “Nanotechnology Research: Congress Wants Studies of Nanotech's ‘Dark Side,’”Science301, no. 5629 (2003): 27.
35.
See Theis, supra note 1; PetersonC., Testimony at the Committee on Science, U.S. House of Representatives Hearing to Examine the Societal Implications of Nanotechnology and Consider H.R. 766, The Nanotechnology Research and Development Act of 2003 (April 9, 2003); Institute of Medicine, Nanotechnology and Oncology: Workshop Summary (Washington, D.C.: The National Academies Press, 2011).
36.
See Theis, supra note 1; id. (Peterson); (Institute of Medicine).
37.
Salamanca-BuentelloF.PersadD. L.CourtE. B.MartinD. K.DaarA. S., and SingerP. A., “Nanotechnology and the Developing World,”PLoS Medicine2, no. 5 (2005): E97.
38.
FerrariM., “Session 5: Nanotechnology, Medicine, and Ethics,” testimony at the President's Council on Bioethics, June 7, 2007, available at <http://bioethics.georgetown.edu/pcbe/transcripts/june07/session5.html> (last visited October 30, 2012); FerrariM., “Cancer Nanotechnology: Opportunities & Challenges,”Nature5, no. 3 (2005): 161–171; SanhaiW. R.SakamotoJ. H.CanadyR., and FerrariM., “Seven Challenges for Nanomedicine,”Nature Nanotechnology3, no. 5 (2008): 242–244; see Theis, supra note 1; Peterson, supra note 35; Institute of Medicine, supra note 35; MaynardA. D., “Don't Define Nanomaterials,”Nature475, no. 7354 (2011): 31; MaynardA. D.WarheitD. B., and PhilbertM. A., “The New Toxicology of Sophisticated Materials: Nanotoxicology and Beyond,”Toxicological Sciences120, Supp. 1 (2011): S109–S129; MaynardA. D., “Session 4: Nanotechnology: Benefits and Risks,”The President's Council on Bioethics, June 29, 2007, available at <http://bioethics.georgetown.edu/pcbe/transcripts/june07/session4.html> (last visited October 30, 2012).
39.
Id. (Ferrari); Sanhai, supra note 38.
40.
See Theis, supra note 1; Peterson, supra note 35; Institute of Medicine, supra note 35; Maynard (Nature), supra note 38; Maynard (Toxicological Sciences), supra note 38; Maynard (The President's Council on Bioethics), supra note 38.
41.
See Maynard (Nature), supra note 38; Maynard (Toxicological Sciences), supra note 38.
42.
See Maynard (Nature), supra note 38.
43.
See Maynard (President's Council on Bioethics), supra note 38.
44.
NelA.XiaT.MädlerL., and LiN., “Toxic Potential of Materials at the Nanolevel,”Science311, no. 5761 (2006): 622–627; ZhaoF.ZhaoY.LiuY.ChangX.ChenC., and ZhaoY., “Cellular Uptake, Intracellular Trafficking, and Cytotoxicity of Nanomaterials,”Small7, no. 10 (2011): 1322–1337.
45.
ZhaoY.XingG., and ChaiZ., “Nanotoxicology: Are Carbon Nanotubes Safe?”Nature Nanotechnology3, no. 4 (2008): 191–192.
46.
See Ferrari (President's Council on Bioethics), supra note 38; Maynard (Toxicological Sciences), supra note 38.
47.
See Institute of Medicine, supra note 35.
48.
Id.
49.
ParadiseJ.WolfS. M.KuzmaJ.KuzhabekovaA.TisdaleA. W.KokkoliE., and RamachandranG., “Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences,”Journal of Law, Medicine & Ethics37, no. 4 (2009): 688–705.
50.
See Maynard (Nature), supra note 38.
51.
FerrariM.PhilibertM. A., and SanhaiW. R., “Nanomedicine and Society,”Clinical Pharmacology & Therapeutics85, no. 5 (2009): 466–467.
52.
BlackE., War Against the Weak (New York: Four Walls Eight Windows, 2003); ProctorR. N., Racial Hygeine: Medicine Under the Nazis (Cambridge: Harvard University Press, 1988).
53.
FerlayJ.ShinH. R.BrayF.FormanD.MathersC., and ParkinD. M., “GLOBOCAN 2008,” v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10, Lyon, France: International Agency for Research on Cancer, 2010, available at <http://globocan.iarc.fr> (last visited October 31, 2012; for statistics cited, search under “Online Analysis” link).
54.
National Center for Health Statistics, “Deaths: Final Data for 2009,” at table 9, National Vital Statistics Reports, Volume 60, Number 03, 117 pp. (PHS) 2012–1120, available at <http://www.cdc.gov/nchs/products/nvsr.htm> (last visited November 6, 2012).
55.
FodorS. P.ReadJ. L.PirrungM. C.StryerL.LuA. T., and SolasD., “Light-Directed, Spatially Addressable Parallel Chemical Synthesis,”Science251, no. 4995 (1991): 767–773.
56.
See Maynard (President's Council on Bioethics), supra note 38.
57.
See Ferrari (2005 and 2010), Salvador-Morales, and Langer, supra note 9; Maier-Hauff, supra note 15.
58.
See Barenholz, supra note 11.
59.
Id.
60.
See Maier-Hauff, supra note 15.
61.
See Ferrari (2010), supra note 9.
62.
RejeskiD., “Comments of Consumers Union of United States, Inc. to the U.S. Consumer Product Safety Commission on ‘Agenda, Priorities and Strategic Plan FY 2011,’” Panel 1, Consumer Product Safety Comissions: Public Hearing Commission Agenda, Priorities and Strategic Plan for FY2011, Bethesda, MD, August 25, 2009, available at <http://www.cpsc.gov/library/foia/foia09/pubcom/2011priorities.pdf> (last visited October 31, 2012).
63.
See Nel and Zhao, supra note 44; Zhao, supra note 45.
64.
See Ferrari (2010), supra note 9.
65.
RhodesR., The Making of the Atomic Bomb (New York: Simon & Schuster, 1987).
66.
SpecterM., “The Deadliest Virus,”The New Yorker, March 12, 2012, at 32; EnserinkM., “Scientists Brace for Media Storm around Controversial Flu Studies,”ScienceInsider, November 23, 2011; EnserinkM., “Free to Speak, Kawaoka Reveals Flu Details While Fouchier Stays Mum,”ScienceInsider, April 3, 2012; EnserinkM., “One of Two Hotly Debated H5N1 Papers Finally Published,”Science Now, May 2, 2012; ImaiM.WatanabeT.HattaM.DasS. C.OzawaM.ShinyaK.ZhongG.HansonA.KatsuraH.WatanabeS.LiC.KawakamiE.YamadaS.KisoM.SuzukiY.MaherE. A.NeumannG., and KawaokaY., “Experimental Adaptation of an Influenza H5 HA Confers Respiratory Droplet Transmission to a Reassortant H5 HA/H1N1 Virus in Ferrets,”Nature486, no. 7403 (2012): 420–428.
67.
Committee on Opportunities in Biotechnology for Future Army Applications, Board on Army Science and Technology, Division on Engineering and Physical Sciences, National Research Council, Opportunities in Biotechnology for Future Army Applications (Washington, D.C.: The National Academies Press, 2001): at 11–15.
68.
National Materials Advisory Board and Board on Army Science and Technology, Division on Engineering and Physical Sciences, National Research Council, Opportunities in Protection Materials Science and Technology for Future Army Applications (Washington, D.C.: The National Academies Press, 2011): at 11–15.
69.
CrichtonM., Prey (New York: HarperCollins, 2002).
70.
SoongR. K.BachandG. D.NevesH. P.OlkhovetsA. G.CraigheadH. G., and MontemagnoC. D., “Powering an Inorganic Nanodevice with a Biomolecular Motor,”Science290, no. 5496 (2000): 1555–1558.
71.
Institute of Medicine's Committee on Genomics and the Public's Health in the 21st Century and HernandezL. M., ed., “Implications of Genomics for Public Health: Workshop Summary,” in The National Academies Collection: Reports Funded by National Institutes of Health (Washington, D.C.: National Academies Press, 2005).
72.
Id.
73.
MurphyC. G. and FornierM., “HER2-Positive Breast Cancer: Beyond Trastuzumab,”Oncology (Williston Park)24, no. 5 (2010): 410–415.
74.
See Ferlay, supra note 53.
75.
Id.; DennyL., “Cervical Cancer Treatment in Africa,”Current Opinion in Oncology23, no. 5 (2011): 469–474.
76.
Cardenas-TuranzasM.FreebergJ. A.BenedetJ. L.AtkinsonE. N.CoxD. D.Richards-KortumR.MacAulayC.FollenM., and CantorS. B., “The Clinical Effectiveness of Optical Spectroscopy for the In Vivo Diagnosis of Cervical Intraepithelial Neoplasia: Where Are We?”Gynecologic Oncology107, Supp. 1 (2007): S138–S146; Richards-KortumR., Biomedical Engineering for Global Health (Cambridge, U.K.: Cambridge University Press, 2010).
77.
See Ferrari, supra note 51.
78.
BosettiR., Cost Effectiveness of Cancer Nanotechnology, Dissertation, D/2012/2451/8 (Belgium: Hasselt University, 2012).